Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

NCT03605719 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma

Interventions

DRUG: Carfilzomib
DRUG: Dexamethasone
BIOLOGICAL: Nivolumab
BIOLOGICAL: Pelareorep

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]